AMPLIMED SECURES $5 MILLION SERIES B FINANCING

AmpliMed Corporation today announced the completion of a Series B Preferred private placement of approximately $5 million. Led by Biotech Insight Ventures, previous investors including InvestBio Ventures, Valley Ventures and Solstice Capital also participated in the round. To date, AmpliMed has raised more than $14 million in financing. "The fact that our investors continue to support AmpliMed underscores their commitment to our clinical development program and our pipeline of anti-cancer therapies. This is an exciting time for the company as our Amplimexon clinical development program is expanding rapidly and we plan to bring additional new drugs into clinical trials in the near future," said Robert A. Ashley, chairman, president and CEO of AmpliMed.
Genetic Engineering News